| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$12 |
1HFY26 Appendix 4D and Half Year Report
|
26 Feb 2026 10:48AM |
$0.110 |
$0.089 |
fallen by
19.55%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- ReNerve Limited reported a $2,716,555 loss for the half-year ending 31 December 2025.
- Losses increased by 47.3% compared to the previous year.
- The company is shifting focus from R&D to commercial operations.
- ReNerve's product lines, NervAlign® and Empliq, are expanding in US and Asian markets.
- There were no dividends declared during this financial period.
- The company is enhancing its presence with new partnerships and product launches.
- ReNerve aims to expand its operations in Asia Pacific and refine its US business.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$16 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:46AM |
$0.335 |
$0.195 |
fallen by
41.79%
|
|
CHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of $2,927,551 for the half-year ended 31 December 2025.
- Revenue decreased slightly to $19,055,500 from $19,951,782.
- Camplify Holdings Limited includes operations in multiple countries.
- Equity raised through the issue of shares increased to $88,417,795.
- Significant cash flow improvements with closing cash at $23,177,629.
- No dividends declared during the period.
- Cost reduction programs and new operations launched.
- Positive outlook for H2FY26 results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Hemisphere Mining Limited (SUH) ORDINARY FULLY PAID |
Materials |
$14 |
Broad Intersections of Mineralised Porphyry at Target K
|
26 Feb 2026 10:45AM |
$0.032 |
$0.019 |
fallen by
40.63%
|
|
SUH - Price-sensitive ASX Announcement
Full Release
Key Points
- Drillhole 26LHDD072 completed to a depth of 1,038.2m at Target K.
- Multiple broad intersections of mineralised porphyry phases identified.
- Visible copper and molybdenum observed in quartz–sulphide veinlets.
- Structural data suggests further exploration vectors south and east.
- Ongoing geophysical data processing to support exploration modeling.
- Llahuin Copper-Gold-Molybdenum Project located in Chile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scout Security Limited (SCT) ORDINARY FULLY PAID |
Consumer Discretionary |
- |
Appendix 4E
|
26 Feb 2026 10:43AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| HomeCo Daily Needs REIT (HDN) ORDINARY UNITS FULLY PAID |
Real Estate |
$2,601 |
Application for quotation of securities - HDN
|
26 Feb 2026 10:41AM |
$1.295 |
$1.245 |
fallen by
3.86%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$12,757 |
Change of Director's Interest Notice - Anthony Hall
|
26 Feb 2026 10:39AM |
$125.010 |
$122.110 |
fallen by
2.32%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$13 |
Streamplay H1 FY26 Results Summary
|
26 Feb 2026 10:38AM |
$0.010 |
$0.010 |
risen by
5.26%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$13 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:38AM |
$0.010 |
$0.010 |
risen by
5.26%
|
|
SP8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 85% to $8,502,721.
- Net profit after tax was $571,621, up from a loss of $177,809.
- Noodlecake Studios significantly contributed to revenue growth.
- Continued operations in Middle East & Africa and Asia Pacific.
- Cash and cash equivalents at $8.55 million as of 31 December 2025.
- Focus on cost management and operational efficiency.
- No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$49 |
Investor Presentation
|
26 Feb 2026 10:37AM |
$0.036 |
$0.042 |
risen by
16.67%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$662 |
FY2025 Full Year Results Q&A Webinar
|
26 Feb 2026 10:36AM |
$1.615 |
$1.650 |
risen by
2.17%
|
|
| Ambertech Limited (AMO) ORDINARY FULLY PAID |
Information Technology |
$10 |
Investor Presentation - 1H FY26 Results
|
26 Feb 2026 10:36AM |
$0.130 |
$0.105 |
fallen by
19.23%
|
|
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$515 |
Entitlement Offer Booklet
|
26 Feb 2026 10:34AM |
$1.860 |
$1.865 |
risen by
0.27%
|
|
| Ardiden Limited (ADV) ORDINARY FULLY PAID |
Materials |
$90 |
Change in substantial holding
|
26 Feb 2026 10:33AM |
$0.495 |
$0.420 |
fallen by
15.15%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$147 |
ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
|
26 Feb 2026 10:27AM |
$0.041 |
$0.041 |
fallen by
0%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of accelerated enrolment in XanaMIA phase 2b/3 Alzheimer's trial with 247 participants.
- Positive interim safety and efficacy analysis from DMC for XanaMIA trial.
- Open-label extension phase of XanaMIA trial to commence in Q1 2026.
- Agreement with FDA on streamlined design for pivotal trial of Xanamem 10 mg vs. placebo.
- Completion of commercial-grade manufacture of Xanamem tablets for OLE phase.
- Actinogen received $7.4 million R&D tax incentive for FY2025.
- Net loss of $11.3 million for half-year ended 31 December 2025, primarily due to R&D costs.
- Proforma cash balance of $29.7 million as of 31 December 2025.
- Planning for rapid expansion pending successful phase 2b/3 trial results.
- Xanamem shows promise as a treatment for Alzheimer's with potential safety and efficacy profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$147 |
Actinogen HY2025 financial report and Appendix 4D
|
26 Feb 2026 10:26AM |
$0.041 |
$0.041 |
fallen by
0%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited reported a net loss after tax of $11,346,952 for the half-year ended 31 December 2025, compared to a loss of $8,168,979 for the previous year.
- The company's total revenue and other income increased to $2,107,063 from $244,406 the previous year.
- Research and development costs significantly increased to $8,902,759, reflecting ongoing clinical trials and development activities.
- The company's cash and cash equivalents decreased from $16,504,230 as of 30 June 2025 to $6,531,460 as of 31 December 2025.
- The total equity of Actinogen Medical Limited decreased from $18,335,903 as of 30 June 2025 to $8,368,615 as of 31 December 2025.
- The R&D tax rebate for FY25 amounted to $5,489,600 and was fully received by the company.
- The company issued new shares during the half-year, increasing contributed equity to $116,196,238.
- Actinogen launched an InvestorHub platform in September 2025 to enhance communication with investors.
- The report included a detailed statement of financial position and changes in equity, emphasizing the impact of R&D expenses and share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wide Open Agriculture Ltd (WOA) ORDINARY FULLY PAID |
Consumer Staple |
$9 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:24AM |
$0.016 |
$0.013 |
fallen by
18.75%
|
|
WOA - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for half-year ended 31 December 2025 was $2,052,935.
- Revenue increased by 41% to $381,225 compared to the previous year.
- Focus on cost reduction and capital management to extend cash runway.
- $1.5 million in cash held as of 31 December 2025.
- Strong demand for lupin protein isolate and development of lupin oil and fiber.
- Exploration of contract manufacturing to meet demand and reduce costs.
- Directors believe the company will continue as a going concern.
- Potential R&D tax refund, equity raising, and asset disposals identified as financial strategies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$169 |
Change of Director's Interest Notice - David Haslingden
|
26 Feb 2026 10:22AM |
$0.540 |
$0.435 |
fallen by
19.44%
|
|
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$16 |
Media Release - December 2025 half-years results
|
26 Feb 2026 10:21AM |
$0.078 |
$0.065 |
fallen by
16.67%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for HY26 was $3.1 million, a 9% increase from the prior year.
- AUM grew by 7% to AUD 5.02 billion as of 31 December 2025.
- After-tax loss of $369,179 due to strategic investments.
- Focus on profitability and scalable growth.
- Strong financial position with $7.2 million in cash.
- Continued investment in team and operational capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| K2 Asset Management Holdings Limited (KAM) ORDINARY FULLY PAID |
Financials |
$16 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:20AM |
$0.078 |
$0.065 |
fallen by
16.67%
|
|
KAM - Price-sensitive ASX Announcement
Full Release
Key Points
- K2 Asset Management Holdings Ltd reported a comprehensive loss of $369,179 for the half-year ended 31 December 2025.
- Total revenue for the half-year increased by 8.7% to $3,115,797 compared to the previous corresponding period.
- The company paid a final dividend of 0.50 cents per share, fully franked, on 30 September 2025.
- Employee benefits and marketing expenses were significant cost items impacting financial performance.
- No new equity issuances occurred during the half-year period.
- The company operates solely within Australia's financial services sector.
- Cash and cash equivalents decreased, affecting overall liquidity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Bond Exchange Holdings Limited (ABE) ORDINARY FULLY PAID |
Financials |
$2 |
Application for quotation of securities - ABE
|
26 Feb 2026 10:18AM |
$0.030 |
$0.014 |
fallen by
53.33%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,581 |
Final Director's Interest Notice - Graeme Barclay
|
26 Feb 2026 10:17AM |
$5.130 |
$5.390 |
risen by
5.07%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,581 |
Change of Director's Interest Notice - Phillip Britt
|
26 Feb 2026 10:15AM |
$5.130 |
$5.390 |
risen by
5.07%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,581 |
Change of Director's Interest Notice - Sarah Adam-Gedge
|
26 Feb 2026 10:15AM |
$5.130 |
$5.390 |
risen by
5.07%
|
|
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$115 |
Update - Dividend/Distribution - ANG
|
26 Feb 2026 10:15AM |
$0.183 |
$0.185 |
risen by
1.37%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,581 |
Change of Director's Interest Notice - Sue Klose
|
26 Feb 2026 10:15AM |
$5.130 |
$5.390 |
risen by
5.07%
|
|
Call 1300 880 160
Start a chat
Schedule a call
